Since the first clinical application of human umbilical cord blood (UCB) (Gluckman et al., 1989) , there has been an increasing use of UCB as an alternative to bone marrow and mobilized peripheral blood source of transplantable hematopoietic stem/progenitor cells (HSPC). More than 1000 cord blood transplantations have been performed to date, in patients with various disorders, including malignant diseases, bone marrow failures, hemoglobinopathies and inborn errors of metabolism (Gluckman, 2000) .
The umbilical cord blood-derived HSPC differ from their counterparts present in adult bone marrow or in mobilized peripheral blood. The content of hematopoietic progenitor cells is similar in UCB and in adult bone marrow, however, the former contains a higher proportion of primitive hematopoietic cells, such as the multipotent colony forming cells (Hows et al., 1992; , long-term culture-initiating cells (Pettengell et al., 1994) and SCID-repopulating cells (Wang et al., 1997) . It has been demonstrated that the proliferative potential of UCB-derived HSPC is higher than that of adult bone marrow or peripheral blood cells (Hows et al., 1992; Traycoff et al., 1994; Mayani & Lansdorp, 1998) . Due to the low alloreactivity of UCB lymphocytes the incidence and severity of the graft-versus-host disease after UCB transplantation was reduced, when compared to bone marrow grafts even in the case of partially HLA-mismatched patients (Gluckman, 2000) .
Gene therapy offers a strategy of treatment of various acquired and genetic disorders. The HSPC are an attractive target for gene incorporation, because they can be easily isolated, genetically modified ex vivo and, after verifying their functional status, transplanted to the patient. The transplantation should result in long-term repopulation of hematopoietic and immune systems with a sufficient contribution of genetically modified cells (Capel et al., 1990) . However, for the two decades since the development of gene delivery technology, foreign gene expression in HSPC has been difficult to achieve. A successful attempt of clinical application of gene therapy has to involve (i) optimisation of short-term culture conditions preventing apoptosis and supporting the divisions of cells without a loss of their pluripotency; and (ii) optimisation of gene transfer strategy to increase its efficiency without the reduction of cell viability and alteration of the functional status of the HSPC.
Several approaches have been taken to incorporate foreign DNA into HSPC. The most commonly used are viral and nonviral vectors delivered via different ways. Here we describe transient transfection of HSPC by electroporation with efficiency comparable to that of other DNA delivery methods.
MATERIALS AND METHODS
Cell isolation. Cord blood samples, collected from full-term normal deliveries, were diluted 1:1 with phosphate-bufferd saline (PBS) (Gibco). Subsequently, mononuclear cells were isolated by centrifugation on Ficoll (Sigma; 1.077 g/ml) at 400´g for 40 min. The mononuclear cells were collected, washed twice in IMDM (Gibco) supplemented with 10% FCS (Cytogen) and resuspended in PBS with the addition of 0.5% human serum albumin (HSA) (Biomed).
The CD34 + fraction was isolated immunomagnetically using MS+ MiniMACS columns and the CD34 Direct Isolation Kit (Miltenyi Biotec) according to the manufacturer recommendations. In brief, after adding FcR Blocking Reagent, cells were labelled with MACS CD34 Microbeads for 30 min at 6-12°C. Subsequently, the labelled cells were enriched by passing the cell suspension through a column placed in a magnetic field. The positively selected cells were removed from the magnetic field and washed out from the column. The purity of the CD34 + cell population was determined by flow cytometry immediately after isolation.
Cell stimulation, electroporation, and posttransfection incubation. Target cells were cultured in 25 cm 2 flasks at a cell density of 1´10 5 /ml in a serum-free medium for hematopoietic stem and progenitor cells (CellGro) supplemented with growth factors: stem cell factor (SCF) (20 ng/ml; PeproTech EC), trombopoietin (TPO) (50 ng/ml; PeproTech EC) and Flt-3 ligand (Flt-3L) (50 ng/ml; PeproTech EC). After 48 hours of incubation at 37°C in a humidified atmosphere of 5% CO 2 , cells were resuspended at 11 0 5 /ml in the CellGro medium supplemented with 20% HSA. DNA plasmid (pEGFP-N2; Clontech) carrying EGFP as a reporter gene under control of the CMV promoter, was added to the 400 ml of cell suspension. The electroporation was performed in a 4 mm cuvette using a BTX ECL600 instrument (Gentronix). The voltage was set at 550 V/cm. The capacitances and the amount of DNA used for electroporation are shown in Table 1 and 
RESULTS
In our study we evaluated the effect of electroporation conditions (pulse capacitance and DNA concentration) on the transfection efficiency and the viability of the UCB-derived CD34 + cells. As demonstrated in Fig. 2C , cells pulsed in the presence of the DNA and incubated in the CellGro medium supplemented with TPO/SCF/Flt-3L for 48 h showed expression of EGFP. The highest (over 40%) percentage of cells expressing the reporter gene was observed among the CD34 + cells electroporated with the capacitances of 1600 mF and 2400 mF. However, application of the latter capacitance resulted in a significant decrease of cell viability (Table 1) . We also examined the effect of DNA concentration on the effectiveness of gene delivery. CD34 + cells were electroporated at the optimal capacitance (1600 mF) and in the presence of various concentrations of plasmid DNA. As it was clearly shown (Table 2) , the increase of transfection efficiency due to the application of high plasmid DNA concentration was paralleled by a decrease of cell viability.
DISCUSSION
Clinical application of genetically modified CD34 + hematopoietic stem/progenitor cells transplantation rapidly becomes an area of intensive investigations. Gene therapy requires an efficient and safe procedure of gene delivery into HSPC. The first attempt at gene delivery into HSPC was the use of adenoviral or retroviral vectors (Baum et al., 1996; Frey et al., 1998 the treatment of disorders requiring stable gene integration into the genome of target cells and the efficiency of retroviral vectors is usually poor (Corrias et al., 1998) . Virus-mediated gene incorporation typically includes the long-lasting stimulation with growth factors (von Kalle et al., 1994) , which causes HSPC differentiation and loss of their self-renewing capacity (Corrias et al., 1998) . Moreover, a number of diseases (i.e. some leukemias and lymphomas) are resistant to virus-mediated gene delivery (Brenner, 1997) . Electroporation is an attractive method of gene transfer into HSPC for clinical applications because it is free from biological contamination and possibility of immune reaction.
Electrotransfection results in sustained foreign gene expression in CD34 + cells (Toneguzzo & Keating, 1986; Van Tendeloo et al., 2000; Wu et al., 2001a) . In this paper we report the optimisation of gene incorporation parameters into CD34 + cells derived from UCB. Enrichment of CD34 + cells on immunomagnetic columns allowed us to perform the experiments with a pure population of these cells (Fig. 3) . The plasmid carrying an enhanced version of green fluorescent protein (EGFP) used in our experiment is a frequently applied marker of gene incorporation (Chalfie et al., 1994) . Cells expressing this molecule become fluorescent and detectable by flow cytometry or fluorescent microscopy (Bierhuizen et al., 1997; Limon et al., 1997; Persons et al., 1997) . To assess proliferating cells, a condition necessary for non-retroviral plasmid incorporation into the target genome, we stimulated cell divisions by the addition of TPO, SCF and Flt-3L to a serum-free medium. As reported previously, such medium promotes rapid exit from G 0 phase, but prevents cell differentiation (Li et al., 2001) . It has been demonstrated that short-term culture of CD34 + cells in a TPO/SCF/Flt-3L serum-free medium resulted in an increase of the cycling CD34 + cells fraction and in augmenting the efficiency of reporter gene transfer. Supplementation of the serum-free medium with other growth factor (IL-3) had no further effect on cell expansion and the efficiency of gene delivery (Wu et al., 2001b) . At the optiVol. 49 CD34 + cells transfection 629 mised conditions of electroporation (1600 mF, 550 V/cm, 10 mg of plasmid DNA per 400 ml of cell culture) we obtained expression of the reporter gene (EGFP) in more than 40% of treated cells (Fig. 4) with high cell viability. Although further increase of the pulse capacitance and DNA concentration resulted in higher transfection efficiency, it caused greater cell death due to the "electroporation toxicity" (Li et al., 2001) . The obtained efficiency of transfection of CD34 + cells isolated from umbilical cord blood was comparable to previous studies on UCB -(Wu et al., 2001c) and peripheral blood-derived (Wu et al., 2001a) HSPC and was higher than that determined for adult bone marrow cells (Van Tendeloo et al., 2000) . This high gene transfer efficiency might be due to the immature status of umbilical cord blood CD34 + cells. Some authors suggest that transfection capacity of more differentiated progenitors is lower than with the primitive cells (Wu et al., 2001c) . Further investigations are necessary to evaluate the correlation between the hematopoietic cell maturation and the efficiency of their transfection. It is also of interest whether the transfected CD34 + cells remain capable of foreign gene expression after their differentiation into fully matured blood cells.
In conclusion, the high frequency of transfection without a marked viability decrease justifies recommendation of electroporation as an efficient method of gene incorporation into UCB derived CD34 + cells. 
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